MPR1d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
Disability Scoop5d
FDA Green-Lights First Treatment For Prader-Willi Syndrome
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
Managed Healthcare Executive5d
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
Pharmaceutical Technology on MSN5d
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
MedPage Today5d
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
BioWorld5d
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars
Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...
Healio5d
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...
Asianet Newsable on MSN5d
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company ...